• 1
    Delaissé JM, Vaes G 1992 Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: RifkinBR, GayCV (eds.) Biology and Physiology of the Osteoclast. CRC Press, Boca Raton, FL, USA, pp. 289314.
  • 2
    Everts V, Delaissé JM, Korper W, Niehof A, Vaes G, Beertsen W 1992 Degradation of collagen in the bone resorbing compartment underlying the osteoclasts involves both the cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 150:221231.
  • 3
    Everts V, Delaissé JM, Korper W, Beertsen W 1998 Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 9:14201430.
  • 4
    Delaissé JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferrera M, Lund L, Vu TH, Werb Z, Winding B, Lochter A, Karsdal MA, Troen T, Kirkegaard T, Lenhard T, Heegaard AM, Neff L, Baron R, Foged NT 2000 Proteinases in bone resorption: Obvious and less obvious roles. Clin Chim Acta 291:223234.
  • 5
    Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, Kumegawa M 1994 Molecular cloning of a possible cysteine proteinases predominantly expressed in osteoclasts. J Biol Chem 269:11061109.
  • 6
    Gelb BD, Shi GP, Chapman HA, Desnick RJ 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:12361238.
  • 7
    Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Detlev Moritz J, Schu P, Von Figura K 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice. Proc Natl Acad Sci USA 95:1345313458.
  • 8
    Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I 1999 Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:16541663.
  • 9
    Garnero P, Borel O, Byrjalsen O, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM 1998 The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:3234732352.
  • 10
    Delaissé JM, Eeckhout Y, Neff L, Francois-Gillet C, Henriet P, Su Y, Vaes G, Baron R 1993 (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment. J Cell Sci 106:10711082.
  • 11
    Rubin C, Sun YQ, Hadjiargyrou M, McLeod K 1999 Increased expression of matrix metalloproteinase-1 in osteocytes precedes bone resorption as stimulated by disuse: Evidence for autoregulation of the cell's mechanical environment? J Orthop Res 17:354361.
  • 12
    Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T 1998 Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology 139:13381345.
  • 13
    Bord S, Horner A, Hembry RM, Reynolds JJ, Compston JE 1997 Distribution of matrix metalloproteinases and their inhibitor TIMP-1, in developing human osteophytic bone. J Anat 191:3948.
  • 14
    Sato T, Ovejero MC, Hou P, Heegard AM, Foged NT, Delaissé JM 1997 Identification of the membrane type matrix metalloproteinase MT1-MMP in osteoclasts. J Cell Sci 110:589596.
  • 15
    Dew G, Murphy G, Stanton H, Vallon R, Angel P, Reynolds JJ, Hembry RM 2000 Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone. Cell Tissue Res 299:385394.
  • 16
    Fuller K, Chambers TJ 1995 Localisation of mRNA for collagenase in osteocytic, bone surface and chondrocytic cells but not osteoclasts. J Cell Sci 108:22212230.
  • 17
    Blavier L, Delaissé JM 1995 Matrix metalloproteinases are obligatory for the migration of (pre)osteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 108:36493659.
  • 18
    Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL 1997 Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 272:2205322058.
  • 19
    Parikka V, Lehenkari P, Sassi ML, Halleen J, Risteli J, Härkönen P, Väänänen HK 2001 Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 142:53715378.
  • 20
    Karsdal MA, Fjording MS, Foged NT, Delaissé JM, Lochter A 2001 Transforming growth factor-β induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276:3935039358.
  • 21
    Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W 2002 The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:7790.
  • 22
    Hanson DA, Weiss MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:12511258.
  • 23
    Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. 39: 635640.
  • 24
    Bonde B, Qvist P, Fledelius C, Riss BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:20222025.
  • 25
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337349.
  • 26
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J 2000 The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11(Suppl 6):S2S17.
  • 27
    Garnero P, Shih WJ, Gineyts E, Karpf D, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate. J Clin Endocrinol Metab 79:16931700.
  • 28
    Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I 1996 Markers of type I collage degradation and synthesis in the monitoring of treatment responses in bone metastases from breast cancer. Br J Cancer 73:10741079.
  • 29
    Kylmälä T, Tammela TLJ, Risteli L, Risteli J, Konttri M, Elomaa I 1995 Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71:10611064.
  • 30
    Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E 1997 Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76:760764.
  • 31
    Elomaa I, Virkkunen P, Risteli L, Risteli J 1992 Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful marker prognostic marker in multiple myeloma. Br J Cancer 66:337341.
  • 32
    Garnero P 2001 Markers of bone turnover in prostate cancer. Cancer Treat Rev 27:187192.
  • 33
    Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J 2000 Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 26:367373.
  • 34
    Linnevers CJ, McGrath ME, Armstrong R, Mistry FR, Barnes MG, Klaus JL, Palmer JT, Katz BA, Brömme D 1997 Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Sci 6:919921.
  • 35
    Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H 1992 Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 285:603611.
  • 36
    Knight CG 1995 Active-site titration of peptidases. Methods Enzymol 248:85101.
  • 37
    Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M, Hanada KL 1982 trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 210:189198.
  • 38
    Brown PD, Giavazzi R 1995 Matrix metalloproteinase inhibition: A review of anti-tumour activity. Ann Oncol 6:967974.
  • 39
    Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Schaefer ME, Stack R, Sullivan M, Summers B, Tressler R, Tyrell D, Allen SD, Castello JJ, Schultz GS, Fernandez LA, Eisher SJ, Cui TY, Foellmer HG, Grobelny D, Holleran WF 1994 Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 732:315323.
  • 40
    Winding B, NicAmhlaoibh R, Misander H, Høegh-Andersen P, Levin Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brünner N, Delaissé JM 2002 Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 8:19321939.
  • 41
    Osterman T, Kippo K, Lauren L, Pasanen I, Hannuniemi R, Sellman R 1997 A comparison of clodronate and indomethacin in the treatment of adjuvant arthritis. Inflamm Res 46:7985.
  • 42
    Everts V, Korper W, Jansen DC, Steinfort J, Lammerse I, Heera S, Docherty AJ, Beertsen W 1999 Functional heterogeneity of osteoclasts: Matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 13:12191230.
  • 43
    Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb BD 1999 Determination of bone markers in pycnodysostosis: Effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:19021908.
  • 44
    Woessner JF, Nagase H 2000 Matrix metalloproteinases and TIMPs. The Protein Profile Series. Oxford University Press, New York, NY, USA
  • 45
    Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M 2001 Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:17391746.
  • 46
    Foged NT, Delaissé JM, Hou P, Lou H, Sato T, Winding B, Bonde M 1996 Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay. J Bone Miner Res 11:226237.
  • 47
    James IE, Lark MW, Zembryki D, Lee-Rykaczewski EV, Hwang SM, Tomaszek TA, Belfiore P, Gowen M 1999 Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents. J Bone Miner Res 14:15621569.
  • 48
    Delaissé JM, Eeckhout Y, Vaes G 1988 Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of collagenase in bone tissue. Endocrinology 123:264276.
  • 49
    Chambers TJ, Fuller K 1985 Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 76:155165.
  • 50
    Jilka RL 1989 Procollagenase associated with the noncalcified matrix of bone and its regulation by parathyroid hormone. Bone 10:353358.
  • 51
    Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W 2001 A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer 37:106113.
  • 52
    Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML 2002 Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2:1725.
  • 53
    Gack S, Vallon R, Schmidt J, Grigoriadis A, Tuckermann J, Schenkel J, Weiher H, Wagner EF, Angel P 1995 Expression of interstitial collagenase during skeletal development of the mouse is restricted to osteoblast-like cells and hypertrophic chondrocytes. Cell Growth Differ 6:759767.
  • 54
    Stahle-Backdähl M, Sandstedt B, Bruce K, Lindahl A, Jiménez MG, Vega JA, López-Otín C 1997 Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and rheumatoid arthritis. Lab Invest 76:717728.
  • 55
    Zhao W, Byrne MH, Boyce BF, Krane SM 1999 Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest 103:517524.
  • 56
    Inada M, Wang Inada M, Wang Y, Byrne MH, Miyaura C, Krane SM 2001 Mice with null mutation in collagenase-3 (MMP-13) exhibit altered bone remodelling and increased bone mass. J Bone Miner Res 16:S149.
  • 57
    Garnero P, Delmas PD 2003 Investigation of bone: Bone turnover. In: HochbergMC, SilmanAJ, SmolenJS, WeinblattME, WeismanMH (eds.) Rheumatology, 3rd ed. Harcourt Health Sciences Ltd, London, UK. (in press).
  • 58
    Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M, Cerutti S, Frezet MM, Stivanello M, Sacchetto G, Angeli A 1999 Differential patterns of bone turnover in relation to bone pain and disease extent in bone cancer with skeletal metastases. Clin Chem 45:12401247.
  • 59
    Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E 1997 Correlation between bone metabolic marker and bone scan in prostatic cancer. J Urol 157:539543.
  • 60
    Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K, Heickendorff L, Nielsen JL, Erisksen EF 2000 Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64:121129.
  • 61
    Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, Noma H, Kumazawa J 1999 Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) in the assessment and monitoring of bone metastases in prostate cancer. Prostate 39:17.
  • 62
    Lhotak S, Elavathil LJ, Vukmirovic-Popovic S, Duivenvoorden WC, Tozer RG, Singh G 2000 Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis 18:463470.
  • 63
    Wahlgren J, Maisi P, Sorsa T, Sutinen M, Tervahartiala T, Pirila E, Teronen O, Hietanen J, Tjaderhane L, Salo T 2001 Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions. J Pathol 194:217224.
  • 64
    Burleigh MC 1977 Degradation of collagen by non-specific proteinases. In: BarrettA (ed.) Proteinases in Mammalian Cells and Tissues. Biomedical Press, Amsterdam, The Netherlands, pp. 285309.
  • 65
    Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M 1996 Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:1251112516.
  • 66
    Lee ER, Lamplugh L, Shepard NL, Mort JS 1995 The septoclast, a cathepsin B-rich cell involved in the resorption of growth plate cartilage. J Histochem Cytochem 43:525536.